Genentech Avastin Account Orders Double, Reorder Rate Improves To 80%
Executive Summary
Eighty percent of Genentech's accounts are currently placing reorders for the colorectal cancer therapy Avastin
You may also be interested in...
Genentech Rituxan Sales Level Off; Manufacturing Issues Resolved
Sales of Genentech's Rituxan appear to be leveling off as the product approaches full penetration in its largest markets
Genentech Rituxan Sales Level Off; Manufacturing Issues Resolved
Sales of Genentech's Rituxan appear to be leveling off as the product approaches full penetration in its largest markets
Genentech Avastin Early Sales Data Suggest Broad Use In Colorectal Cancer
Genentech is receiving public reimbursement for use of Avastin in both first-line and relapsed/refractory metastatic colorectal cancer, the company told investors April 8